GANGA PHARMA H1 : STANDALONE NET PROFIT DOWN 25% AT ₹1.86 L (YOY), DOWN 75.7% (QOQ). WEAK (ON 1ST LOOK)

Revenue up 3.6% at ₹1.42 Cr (YOY), down 1.1% (QOQ). Ebitda at ₹10.86 L; margins 7.7% v 9.2% (YOY), 13.5% (QOQ).

Ganga Pharmaceuticals Ltd